116,145 results on '"Stomach Neoplasms"'
Search Results
52. Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
53. Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
54. Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
55. Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE) (K-ACCELERATE)
56. Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
57. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)
58. Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
59. Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
60. A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
61. Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
62. Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
63. A Study of SGN-B6A in Advanced Solid Tumors
64. Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
65. RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
66. Effects of the Use of Probiotics on the Intestinal Microbiota of Patients With Gastric Cancer (PRONIC-G)
67. Dual-Port Laparoscopic Distal Gastrectomy for Gastric Cancer
68. Wet Heparinized Suction for Abdominal Cancer (EUS Heparin)
69. A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
70. Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer
71. Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
72. Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer
73. Multimodal Prehabilitation for Resectable Gastric Cancer
74. A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)
75. AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
76. Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG
77. Gastric Cancer Risk Factors Knowledge in European and Latinamerican Population (LEGACY-3)
78. Advanced GC Multi-omic Characterization in EU and CELAC Populations (LEGACY-2)
79. Gastric Cancer Risk Factors Associated With EU and CELAC Populations (LEGACY-1)
80. A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma (ILUSTRO)
81. FMT+SOX+Sintilimab as First-line Treatment for Advanced Gastric Cancer
82. Prediction Model of Occult Omental Metastasis in Patients With Gastric Cancer
83. A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
84. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
85. Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
86. A Pilot Study of the Effect of High Protein Supplement and Exercise Therapy on Preservation of Skeletal Muscle Mass and Quality of Life in Patients With Gastric Cancer and Pancreatic Cancer Treated With Chemotherapy
87. Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.
88. Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
89. Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
90. D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma (GASTRICHIP)
91. Comparison of pCLE and EB in Gastric Lesion Diagnosis
92. Microbiota in Gastric Cancer by Gastric Mucosal Brushing
93. A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
94. Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer
95. Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
96. A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
97. Study of Adjuvant ONO-4538 With Resected Gastric Cancer
98. Study of ONO-4538 in Gastric Cancer
99. Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer
100. Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics Integration
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.